Anti-NKG2A Antibodies and Uses Thereof
AssigneeNovo Nordisk A/S
InventorsPetrus Johannes Louis Spee, Søren Berg Padkær
Life of this patent
Estimating the term…
Abstract
Described herein are anti-NKG2A antibodies suitable for human therapy, including humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and materials for producing and using such antibodies. Exemplary complementarity-determining regions (CDRs) sequences and sites for optional amino acid back-substitutions in framework region (FR) and/or CDRs of such antibodies are also described.
Claims21
An antibody that specifically binds NKG2A, comprising antigen-binding residues from the complementarity-determining regions (CDRs) of murine antibody Z270 and human acceptor framework sequences, wherein at least the 6 C-terminal amino acid residues of the CDR—H2 are the same as those in the variable heavy (VH) domain human acceptor sequence.
An antibody that specifically binds NKG2A, comprising
- (a) a CDR-L1 corresponding to residues 24-34 of SEQ ID NO:4;
- a CDR-L2 corresponding to residues 50-56 of SEQ ID NO:4;
- a CDR-L3 corresponding to residues 89-97 of SEQ ID NO:4;
- a CDR—H1 corresponding to residues 31-35 of SEQ ID NO:5;
- a CDR—H3 corresponding to residues 95-102 of SEQ ID NO:5;
- and
- a CDR—H2 comprising residues 50-59 of SEQ ID NO:5;
- and
- human acceptor framework sequences;
- wherein residues 60-65 in the CDR—H2 are from a VH human acceptor sequence, and wherein the humanized antibody is more effective than an antibody comprising a variable light (VL) sequence corresponding to SEQ ID NO:1 and a VH sequences corresponding to SEQ ID NO:2 in potentiating the cytotoxic activity of a CD94/NKG2A-expressing NK cell.
An antibody that specifically binds NKG2A, the antibody comprising a VH domain that comprises non-human CDR residues and human VH acceptor framework sequences, the VH domain comprising a CDR—H1 corresponding to residues 31-35 of SEQ ID NO:5, a CDR—H2 corresponding to residues 50-65 of SEQ ID NO:5, and a CDR—H3 corresponding to residues 95-102 of SEQ ID NO:5.
Dependencies are inferred from the claim text.